PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/573,890
Filing Date	03-29-06
First Named Inventor	Kazutaka Nakamoto
Art Unit	1625
Examiner Name	Patricia L. Morris
Attorney Docket Number	3939-0118PUS1

U.S. PATENT DOCUMENTS

Examiner Initial *	Cite No. 1	Document Number: Number - Kind Code [2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-2004-0198773	10-07-2004	Hart et al.	
	2	US-2005/0119229	06-02-2005	Ammermann et al.	
	3	US-2006-0270837	11-30-2006	Gravestock et al.	
	4	US-2007/0167493	07-19-2007	Sankaranarayanan	
	5	US-5,371,086	12-06-1994	Takemoto et al.	
	6	US-5,691,136	11-25-1997	Lupski et al.	
	7	US-5,691,336	11-25-1997	Dorn et al.	
	8	US-6,235,728	05-22-2001	Golik et al.	
	9	US-6,414,013	07-02-2002	Facelli et al.	
	10	US-7,179,804	02-20-2007	Amegadzie et al.	
	11	US-7,179,822	02-20-2007	Bunker et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initial *	Cite No. 1	Foreign Patent Document: Country Code [3]	Number [4] Kind Code (if known) [5]	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
	12	EP	0 124 154	11-07-1984			
	13	WO	03-091226	11-06-2003			
	14	WO	03-091227	11-06-2003			
	15	JP	2001-527063	12-25-2001			X
	16	WO	2004-014366	02-19-2004			
	17	JP	2005-526751	09-08-2005			X
	18	JP	2006-519247	08-24-2006			X
	19	WO	2009-084621	07-09-2009			X
	20	JP	S-284935	11-09-1993			X
	21	JP	59-073575	04-25-1984			X

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional) 2. See Kinds codes of USPTO patent Documents. at www.uspto.gov or MPEP 901.04.

3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/573,890
Filing Date	03-29-06
First Named Inventor	Kazutaka Nakamoto
Art Unit	1625
Examiner Name	Patricia L. Morris
Attorney Docket Number	3939-0118PUS1

U.S. PATENT DOCUMENTS

Examiner Initial *	Cite No. 1	Document Number Number - Kind Code [2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initial *	Cite No. 1	Foreign Patent Document Country [3] Code	Number [4] Kind Code (if known) [5]	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
	22	JP	8-175993	07-09-1996			X

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional) 2. See Kinds codes of USPTO patent Documents, at www.uspto.gov or MPEP 901.04.

3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3.) 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	10/573,690
Filing Date	03-29-06
First Named Inventor	Kazutaka Nakamoto
Group Art Unit	
Examiner Name	
Attorney Docket Number	3939-0118PUS1

NON PATENT LITERATURE DOCUMENTS

Examiner Initial *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	23	CHANG et al., "Synthesis and Structure-Activity Relationships of Quaternary Ammonium Cephalosporins with 3-Pyrazolylpyridinium Derivatives," Bioorganic & Medicinal Chemistry Letters (2000) Vol. 10, No. 11, pp. 1211-1214	
	24	CONNORS et al., "Prodrugs in medicine," Overview, Biologicals & Immunologicals, Exp. Opin. Ther. Patents, Vol. 5, No. 9, 1995, pp. 873-885	
	25	Copy of an Office Action from co-pending U.S. Patent Application No. 11/589,126, mailed May 7, 2009	
	26	HATA, "New Approaches to Antifungal Drugs for the Treatment of Fungal and Protozoal Infections, Ravuconazole and Beyond: New Targets and Pre-clinical Strategies," The SMI's 12th Annual Conference. Superbugs and Superdrugs, March 18, 2010, Crowne Plaza London - St. James, 44 pages	
	27	International Search Report dated May 20, 2008 for corresponding International Application No. PCT/JP2008/057851	
	28	ISHIKAWA et al., "TAK-599, a Novel N-Phosphono Type Prodrug of Anti-MRSA Cephalosporin T-91825: Synthesis, Physicochemical and Pharmacological Properties," Bioorganic & Medicinal Chemistry, Vol. 11, pp. 2427-2437, (2003)	
	29	LUKEVICS et al., "Synthesis and cytotoxicity of silyl- and carbonyl-substituted isoxazoles," Chemistry of Heterocyclic Compounds (2000) Vol. 36, No. 10, pp. 1226-1231	
	30	PLATE et al., "Synthesis and Muscarinic Activities of 3-(Pyrazolyl)-1,2,5,6-tetrahydropyridine Derivatives," Bioorganic & Medicinal Chemistry Letters (1996) Vol. 4, No. 2, pp. 227-237	
	31	Supplementary European Search Report dated February 6, 2009 for corresponding European Application No. 04786159.4	
	32	TANAKA et al., "An Effective Lewis Acid-Mediated 1,3-Dipolar Cycloaddition of Nitrile Oxide Using Acetylene: Synthesis of a (2-Aminopyridin-3-yl) isoxazole Derivative and its Application to Novel Antifungal Agents," pp. 1-8	
	33	VRZHESCHCH et al., "Supercooperativity in platelet aggregation: Substituted pyridyl isoxazoles, a new class of supercooperative platelet aggregation inhibitors," FEBS Letters (1994) Vol. 351, No. 2, pp. 168-170	

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.